{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:09:30Z","timestamp":1786990170846,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.hoc.2009.07.008","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T05:16:06Z","timestamp":1255410966000},"page":"1121-1135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Daniel J.","family":"DeAngelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2009.07.008_bib1","first-page":"8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hoc.2009.07.008_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0950-3536(05)80201-X","article-title":"Immunophenotypic classification of acute lymphoblastic leukaemia","volume":"7","author":"Ludwig","year":"1994","journal-title":"Baillieres Clin Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2009.07.008_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428199409052679","article-title":"Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL","volume":"13","author":"Ludwig","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2009.07.008_bib4","series-title":"Leukemia","first-page":"621","article-title":"Acute lymphoblastic leukemia in adults","author":"Hoelzer","year":"2002"},{"key":"10.1016\/j.hoc.2009.07.008_bib5","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2009.07.008_bib6","first-page":"70","article-title":"Treatment of adult acute lymphoblastic leukemia","volume":"24","author":"Laport","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2009.07.008_bib7","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2009.07.008_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1365-2141.1997.4413253.x","article-title":"ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse","volume":"99","author":"Giona","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2009.07.008_bib9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1365-2141.1997.1102926.x","article-title":"Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol","volume":"97","author":"Giona","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2009.07.008_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.2002.03706.x","article-title":"A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood \u2018high-risk\u2019 acute lymphoblastic leukaemia: a study of the AIEOP group","volume":"118","author":"Testi","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2009.07.008_bib11","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2009.07.008_bib12","first-page":"3352","article-title":"2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2009.07.008_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"issue":"Pt B","key":"10.1016\/j.hoc.2009.07.008_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4757-0390-0_59","article-title":"Sensitivity of T-leukemic cells to deoxyguanosine and arabinosyl guanine","volume":"165","author":"Gelfand","year":"1984","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.hoc.2009.07.008_bib15","first-page":"6498","article-title":"Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells","volume":"49","author":"Shewach","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2009.07.008_bib16","first-page":"1008","article-title":"Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts","volume":"45","author":"Shewach","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2009.07.008_bib17","first-page":"3646","article-title":"Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts","volume":"45","author":"Verhoef","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2009.07.008_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1172\/JCI111514","article-title":"Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts","volume":"74","author":"Ullman","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hoc.2009.07.008_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00007890-199110000-00011","article-title":"Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine","volume":"52","author":"Hebert","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.hoc.2009.07.008_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/bi00889a004","article-title":"Synthesis of 9-beta-D-arabinofuranosylguanine","volume":"3","author":"Reist","year":"1964","journal-title":"Biochemistry"},{"key":"10.1016\/j.hoc.2009.07.008_bib21","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1021\/bi00515a048","article-title":"Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases","volume":"20","author":"Krenitsky","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.hoc.2009.07.008_bib22","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2009.07.008_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","article-title":"Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase\u00a0I study of nelarabine for the treatment of refractory hematologic malignancies","volume":"18","author":"Kisor","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2009.07.008_bib24","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","article-title":"Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2009.07.008_bib25","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2009.07.008_bib26","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2009.07.008_bib27","first-page":"47a","article-title":"Compound GW506U78 has high single-drug activity and good feasibility in heavily pretreated relapsed T-lymphoblastic leukemias (T-ALL) and T-lymphoblastic lymphoma (T-LBL) and offers the option for cure with stem cell transplantation (SCT)","volume":"106","author":"G\u00f6kbuget","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2009.07.008_bib28","unstructured":"NCT 00,684,619. Available at: http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.hoc.2009.07.008_bib29","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2009.07.008_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0006-291X(02)00415-1","article-title":"Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity","volume":"293","author":"Lotfi","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.hoc.2009.07.008_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10428199809059234","article-title":"Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia","volume":"31","author":"Kakihara","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2009.07.008_bib32","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","article-title":"Phase I trial of nelarabine in indolent leukemias","volume":"26","author":"Gandhi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2009.07.008_bib33","unstructured":"NCT 00,408,005. Available at: http:\/\/www.clinicaltrials.gov."},{"key":"10.1016\/j.hoc.2009.07.008_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428190600961058","article-title":"Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901","volume":"48","author":"Czuczman","year":"2007","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858809001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858809001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:53:12Z","timestamp":1760183592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858809001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0889858809001464"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2009.07.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2009.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}